HopeStage
Back to all studies
CompletedNCT01213836

Seroquel XR or IR and Thinking Skills in Schizophrenia

About this titleRead the official source — NCT01213836
Medication studyAges 18–50Multiple countries
The study in practice

Understand this study

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 50 years. Other eligibility criteria applied.

Listed locations
Vienna and 19 more locationsSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateNovember 2010
Recruitment status
Completed
Enrollment listed in the registry
75
Sponsor
AstraZeneca
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
Austria, Denmark, Germany, ...
Age range
From 18 Years to 50 Years
Official registry ID
NCT01213836
Official title
Show the full official title

A Phase IV Prospective, Double-blind, Double-dummy, Randomised, Crossover Study to Assess the Impact on Daily Cognitive Functioning of Quetiapine Fumarate Immediate Release (Seroquel IR®) Dosed Twice Daily and Quetiapine Fumarate Extended Release (Seroquel XR®) Dosed Once Daily in the Evening in Patients With Stable Schizophrenia

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Vienna, Austria · Middelfart, Denmark · Berlin, Germany

17 more locations
  • Bochum, Germany
  • Hamburg, Germany
  • München, Germany
  • Rottweil, Germany
  • Giarre, Italy
  • Genova, Italy
  • Lido di Camaiore, Italy
  • Barakaldo (vizcaya), Italy
  • Tivoli, Italy
  • Sant'Arsenio, Italy
  • Sassari, Italy
  • Borgomanero, Italy
  • Catania, Italy
  • Roma, Italy
  • Torre Annunziata, Italy
  • Salamanca, Spain
  • Zamora, Spain

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is AstraZeneca.

Did this study involve medication?

Yes. The study involved medication, including Seroquel XR- quetiapine fumarate extended release, Seroquel IR - quetiapine fumarate, Placebo matching Seroquel XR and Placebo matching Seroquel IR.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 50 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies